Related Experiment Video

Updated: Jul 4, 2026

A Murine Closed-chest Model of Myocardial Ischemia and Reperfusion
13:42

A Murine Closed-chest Model of Myocardial Ischemia and Reperfusion

Published on: July 17, 2012

Anti-arrhythmic effects of kappa-opioid receptor and its changes in ischemia and reperfusion

Liu Jin-Cheng1, Yin Wen, Yin Zhao

  • 1Department of Physiology, National Key Discipline of Cell Biology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China.

Archives of Medical Research
|June 3, 2008
PubMed
Abstract

Insights

Kappa-opioid receptor (kappa-OR) expression increases in the heart during ischemia-reperfusion (I/R). This upregulation enhances the anti-arrhythmic effects of kappa-OR stimulation, offering a potential therapeutic target for I/R-induced arrhythmias.

Area of Science:

  • Cardiology
  • Pharmacology
  • Molecular Biology

Background:

  • The role of kappa-opioid receptors (kappa-OR) in ischemia-reperfusion (I/R) injury remains largely uncharacterized.
  • Investigating alterations in kappa-OR during I/R is crucial for understanding cardiac protection mechanisms.

Purpose of the Study:

  • To determine changes in kappa-opioid receptor (kappa-OR) expression in the heart during I/R.
  • To evaluate the anti-arrhythmic effects of kappa-OR stimulation in an I/R setting.

Main Methods:

  • Utilized a rat model of cardiac ischemia-reperfusion (I/R).
  • Assessed anti-arrhythmic effects using U50,488H (selective kappa-OR agonist) and nor-BNI (selective kappa-OR antagonist).
  • Quantified kappa-OR mRNA and protein levels via RT-PCR and Western blotting.

Main Results:

  • Ischemia-reperfusion significantly increased the incidence of cardiac arrhythmia.
  • Administration of U50,488H reduced arrhythmia incidence in I/R rats, an effect blocked by nor-BNI.
  • Kappa-opioid receptor (kappa-OR) mRNA and protein levels were significantly upregulated in the heart during I/R.

Conclusions:

  • Kappa-opioid receptor (kappa-OR) expression is upregulated in the heart following I/R.
  • This upregulation may potentiate the anti-arrhythmic effects of kappa-OR stimulation during I/R, suggesting a protective role.

More Related Videos

Model of Ischemia and Reperfusion Injury in Rabbits06:11

Model of Ischemia and Reperfusion Injury in Rabbits

Published on: November 3, 2023

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2, D-Pen5]-enkephalin or DPDPE for...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...